45 research outputs found
CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies
Primary cutaneous CD30-positive T-cell lymphoproliferative disorders are the second most common subgroup of cutaneous T-cell lymphomas. They include two clinically different entities with some overlapping features and borderline cases: lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. Molecular studies of primary cutaneous anaplastic large cell lymphoma reveal an increasing level of heterogeneity that is associated with histological and immunophenotypic features of the cases and their response to specific therapies. Here, we review the most significant genetic, epigenetic and molecular alterations described to date in primary cutaneous CD30-positive T-cell lymphoproliferative disorders, and their potential as therapeutic targets
DUSP22-rearranged anaplastic lymphomas are characterized by specific morphological features and a lack of cytotoxic and JAK/STAT surrogate markers
This work was supported by grants from the Instituto de Salud Carlos III (ISCIII) of the Spanish
Ministry of Economy and Competence (MINECO, RTICC ISCIII and CIBERONC) (SAF2013-47416-
R, RD06/0020/0107-RD012/0036/0060 and Plan Nacional I+D+I: PI16/01294 and PIE15/0081),
AECC and the Madrid Autonomous Community
Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features
The overlap of morphology and immunophenotype between angioimmunoblastic T-cell lymphoma (AITL) and other nodal peripheral T-cell lymphomas (n-PTCLs) is a matter of current interest whose clinical relevance and pathogenic background have not been fully established. We studied a series of 98 n-PTCL samples (comprising 57 AITL and 41 PTCL-NOS) with five TFH antibodies (CD10, BCL-6, PD-1, CXCL13, ICOS), looked for mutations in five of the genes most frequently mutated in AITL (TET2, DNMT3A, IDH2, RHOA and PLCG1) using the Next-Generation-Sequencing Ion Torrent platform, and measured the correlations of these characteristics with morphology and clinical features. The percentage of mutations in the RHOA and TET2 genes was similar (23.5% of cases). PLCG1 was mutated in 14.3%, IDH2 in 11.2% and DNMT3A in 7.1% of cases, respectively. In the complete series, mutations in RHOA gene were associated with the presence of mutations in IDH2, TET2 and DNMT3A (p < 0.001, p = 0.043, and p = 0.029, respectively). Fourteen cases featured RHOA mutations without TET2 mutations. A close relationship was found between the presence of these mutations and a TFH-phenotype in AITL and PTCL-NOS patients. Interestingly, BCL-6 expression was the only TFH marker differentially expressed between AITL and PTCL-NOS cases. There were many fewer mutated cases than there were cases with a TFH phenotype. Overall, these data suggest alternative ways by which neoplastic T-cells overexpress these proteins. On the other hand, no clinical or survival differences were found between any of the recognized subgroups of patients with respect to their immunohistochemistry or mutational profile.This work was supported by grants from the Instituto
de Salud Carlos III, from the Ministerio de Economía,
Industria y Competitividad (RTICC RD06/0020/0107,
RD12/0036/0060, PI 12/1682, PT13/0010/0007, PI16/
01294, SAF2013-47416-R, CIBERONC-ISCIII, PIE15/
0081, ISCIII-MINECO AES-FEDER (Plan Estatal I+D+I
2013–2016): PI14/00221, PIE14/0064, PIE15/0081 and
PIE16/01294)) and the Asociación Española Contra el
Cáncer, Spain. JG-R is a recipient of an iPFIS predoctoral
fellowship (IFI14/00003) from ISCIII-MINECO-AESFEDER
(Plan Estatal I+D+I 2013–2016). MSB was
supported by a Miguel Servet contract (CP11/00018)
from the ISCIII-MINECO-AES-FEDER (Plan Nacional
I+D+I 2008–2011), and currently holds a Miguel Servet II
contract (CPII16/00024), supported by ISCIII-MINECOAES-
FEDER (Plan Estatal I+D+I 2013–2016) and the
Fundación de Investigación Biomédica Puerta de Hierro.S
Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the Western world. Pathogenic mechanisms involve multiple external events (such as microenvironmental and antigenic stimuli) and internal events (genetic and epigenetic alterations) that are associated with the transformation, progression and evolution of CLL. CLL is characterized by an accumulation of mature B cells in peripheral blood, bone marrow and lymphoid tissues. Extracellular stimuli play an important role in the development and maintenance of neoplastic cells. B-CLL cells proliferate and activate pathogenic signaling pathways in anatomical structures known as proliferation centers, which are usually more conspicuous in involved lymph nodes.1 Its clinical course is quite heterogeneous, whereby some patients progress rapidly and have short survival, whereas others have a more stable clinical course that may not need treatment for years.This work was supported by grants from the Ministerio de Economía y Competitividad (MINECO) (SAF2013-47416-R) Instituto de Salud Carlos III (ISCIII)- FEDER – MINECO- AES (CP11/00018, PI10/00621, RD012/0036/0060), and Asociación Española contra el Cancer (AECC). MS-B is supported by a Miguel Servet contract from ISCIII-FEDER (CP11/00018). Salary support to SG is provided by CP11/00018, from ISCIII-FEDER. JG-R is supported by a predoctoral grant from the Fundación Investigación Puerta de Hierro.S
Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-cell lymphomas
This work was supported by grants from Asociación
Española contra el Cancer (AECC), Ministerio de Economía y
Competitividad (MINECO) (SAF2013-47416-R), Instituto Salud
Carlos III (ISCIII) – Fondos FEDER, MINECO-AES(RD012/0036/0060, PI10/00621, CP11/00018). RM is supported
by the Fundación Conchita Rábago de la Fundación Jiménez Díaz,
Madrid (Spain). JG-R is supported by a predoctoral grant from the
Fundacion Investigacion Biomedica Puerta de Hierro. Salary support to
SG is provided by ISCIII-FEDER (CP11/00018). MS-B is supported
by a Miguel Servet contract from ISCIII-FEDER (CP11/00018). The
Instituto de Investigación Marqués de Valdecilla (IDIVAL) is partly
funded by the Sociedad para el Desarrollo Regional de Cantabria
(SODERCAN)
An A91V SNP in the perforin gene is frequently found in NK/T-cell lymphomas
NK/T-cell lymphoma (NKTCL) is the most frequent EBV-related NK/T-cell disease. Its clinical manifestations overlap with those of familial haemophagocytic lymphohistiocytosis (FHLH). Since PERFORIN (PRF1) mutations are present in FHLH, we analysed its role in a series of 12 nasal and 12 extranasal-NKTCLs. 12.5% of the tumours and 25% of the nasal-origin cases had the well-known g.272C>T(p.Ala91Val) pathogenic SNP, which confers a poor prognosis. Two of these cases had a double-CD4/CD8-positive immunophenotype, although no correlation was found with perforin protein expression. p53 was overexpressed in 20% of the tumoral samples, 80% of which were of extranasal origin, while none showed PRF1 SNVs. These results suggest that nasal and extranasal NKTCLs have different biological backgrounds, although this requires validation
Experience with a 22 molecular marker predesigned tissue microarray in the preoperative setting of breast cancer treated with FEC-docetaxel, comparing complete responders with incomplete responders, and incomplete responders before and after treatment
C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas
Funding: this study was supported by grants from the Asociación Española contra el Cáncer (AECC), Ministerio de Economía y Competitividad (MINECO) (SAF2013-47416-R), Instituto Salud Carlos III (ISCIII) – Fondos de Investigación Sanitaria (RD06/0020/0107, RD012/0036/0060 and FIS11/1759). The Instituto de Investigación Marqués de Valdecilla (IDIVAL) is partly funded by the Sociedad para el Desarrollo Regional de Cantabria (SODERCAN